Since its FDA approval of XDEMVY® in mid-2023, Tarsus Pharmaceuticals has rapidly scaled revenue but continues to operate at a loss amid substantial investment in commercialization and clinical development. The company's flagship product addresses an unmet need by targeting Demodex mite infestation in blepharitis, positioning it uniquely in the eye care segment. Looking forward, Tarsus is developing extensions for ocular rosacea and Lyme disease prophylaxis using its lotilaner API platform. However, profitability remains elusive with challenging regulatory dynamics, reliance on a single commercial product, and ongoing R&D spending shaping near-term operational results.